Absence of binding of targeted analogs of somatostatin carrying cytotoxic radicals or radionuclides to growth hormone secretagogue receptors on human myocardium

Gabor Halmos, Andrew V Schally, Ana Maria Comaru-Schally, Attila Nagy, Anand Irimpen

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Various peripheral human tissues express receptors for growth hormone secretagogue (GHS), the highest density being in the myocardium. It was also reported that some octapeptide analogs of somatostatin (SRIH) can displace radiolabeled Tyr-Ala-hexarelin from GHS receptors on the human pituitary and heart. Thus, it is possible that radionuclide analogs of SRIH such as OctreoScan® and recently developed cytotoxic SRIH analogs containing doxorubicin (DOX) intended for targeted tumor therapy, could bind to these GHS receptors, compromising the safety of compounds of this type. Therefore, we determined the binding of OctreoScan® and two cytotoxic SRIH analogs consisting of octapeptide carrier RC-121 and DOX (AN-162) or 2-pyrrolino-DOX (AN-238) to human myocardium specimens. None of these compounds displayed specific binding to the human heart indicating that the clinical use of SRIH analogs linked to anthracyclines or radionuclides should not be associated with increased cardiac side effects.

Original languageEnglish
Pages (from-to)2669-2674
Number of pages6
JournalLife Sciences
Volume72
Issue number23
DOIs
StatePublished - Apr 25 2003
Externally publishedYes

Fingerprint

Ghrelin Receptor
Somatostatin
Radioisotopes
Doxorubicin
Myocardium
Anthracyclines
Tumors
Tissue
Safety
Neoplasms
pentetreotide

Keywords

  • Growth hormone secretagogue receptors
  • Human myocardium
  • Targeted somatostatin analogs

ASJC Scopus subject areas

  • Pharmacology

Cite this

Absence of binding of targeted analogs of somatostatin carrying cytotoxic radicals or radionuclides to growth hormone secretagogue receptors on human myocardium. / Halmos, Gabor; Schally, Andrew V; Comaru-Schally, Ana Maria; Nagy, Attila; Irimpen, Anand.

In: Life Sciences, Vol. 72, No. 23, 25.04.2003, p. 2669-2674.

Research output: Contribution to journalArticle

@article{715b346fcdc34c8ba104a4dda473b710,
title = "Absence of binding of targeted analogs of somatostatin carrying cytotoxic radicals or radionuclides to growth hormone secretagogue receptors on human myocardium",
abstract = "Various peripheral human tissues express receptors for growth hormone secretagogue (GHS), the highest density being in the myocardium. It was also reported that some octapeptide analogs of somatostatin (SRIH) can displace radiolabeled Tyr-Ala-hexarelin from GHS receptors on the human pituitary and heart. Thus, it is possible that radionuclide analogs of SRIH such as OctreoScan{\circledR} and recently developed cytotoxic SRIH analogs containing doxorubicin (DOX) intended for targeted tumor therapy, could bind to these GHS receptors, compromising the safety of compounds of this type. Therefore, we determined the binding of OctreoScan{\circledR} and two cytotoxic SRIH analogs consisting of octapeptide carrier RC-121 and DOX (AN-162) or 2-pyrrolino-DOX (AN-238) to human myocardium specimens. None of these compounds displayed specific binding to the human heart indicating that the clinical use of SRIH analogs linked to anthracyclines or radionuclides should not be associated with increased cardiac side effects.",
keywords = "Growth hormone secretagogue receptors, Human myocardium, Targeted somatostatin analogs",
author = "Gabor Halmos and Schally, {Andrew V} and Comaru-Schally, {Ana Maria} and Attila Nagy and Anand Irimpen",
year = "2003",
month = "4",
day = "25",
doi = "10.1016/S0024-3205(03)00181-4",
language = "English",
volume = "72",
pages = "2669--2674",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "23",

}

TY - JOUR

T1 - Absence of binding of targeted analogs of somatostatin carrying cytotoxic radicals or radionuclides to growth hormone secretagogue receptors on human myocardium

AU - Halmos, Gabor

AU - Schally, Andrew V

AU - Comaru-Schally, Ana Maria

AU - Nagy, Attila

AU - Irimpen, Anand

PY - 2003/4/25

Y1 - 2003/4/25

N2 - Various peripheral human tissues express receptors for growth hormone secretagogue (GHS), the highest density being in the myocardium. It was also reported that some octapeptide analogs of somatostatin (SRIH) can displace radiolabeled Tyr-Ala-hexarelin from GHS receptors on the human pituitary and heart. Thus, it is possible that radionuclide analogs of SRIH such as OctreoScan® and recently developed cytotoxic SRIH analogs containing doxorubicin (DOX) intended for targeted tumor therapy, could bind to these GHS receptors, compromising the safety of compounds of this type. Therefore, we determined the binding of OctreoScan® and two cytotoxic SRIH analogs consisting of octapeptide carrier RC-121 and DOX (AN-162) or 2-pyrrolino-DOX (AN-238) to human myocardium specimens. None of these compounds displayed specific binding to the human heart indicating that the clinical use of SRIH analogs linked to anthracyclines or radionuclides should not be associated with increased cardiac side effects.

AB - Various peripheral human tissues express receptors for growth hormone secretagogue (GHS), the highest density being in the myocardium. It was also reported that some octapeptide analogs of somatostatin (SRIH) can displace radiolabeled Tyr-Ala-hexarelin from GHS receptors on the human pituitary and heart. Thus, it is possible that radionuclide analogs of SRIH such as OctreoScan® and recently developed cytotoxic SRIH analogs containing doxorubicin (DOX) intended for targeted tumor therapy, could bind to these GHS receptors, compromising the safety of compounds of this type. Therefore, we determined the binding of OctreoScan® and two cytotoxic SRIH analogs consisting of octapeptide carrier RC-121 and DOX (AN-162) or 2-pyrrolino-DOX (AN-238) to human myocardium specimens. None of these compounds displayed specific binding to the human heart indicating that the clinical use of SRIH analogs linked to anthracyclines or radionuclides should not be associated with increased cardiac side effects.

KW - Growth hormone secretagogue receptors

KW - Human myocardium

KW - Targeted somatostatin analogs

UR - http://www.scopus.com/inward/record.url?scp=0037466270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037466270&partnerID=8YFLogxK

U2 - 10.1016/S0024-3205(03)00181-4

DO - 10.1016/S0024-3205(03)00181-4

M3 - Article

C2 - 12672512

AN - SCOPUS:0037466270

VL - 72

SP - 2669

EP - 2674

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 23

ER -